HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
Jetstar to Charge for Overhead Cabin Bags From February 
Apple Restores Telegram to App Store After Content Policy Violation 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
WINNIPEG, Manitoba, March 16, 2018 -- Kane Biotech Inc. (TSX-V:KNE) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) is pleased to announce that it will host a conference call on Thursday, March 22, 2018 at 4:30pm E.T. to discuss its financial results for the fourth quarter and full year 2017, in conjunction with the filing of its annual Year End Financial Statements for the fourth quarter and full year ended December 31, 2017.
Mark Ahrens-Townsend, President and Chief Executive Officer, and Ray Dupuis, Chief Financial Officer of Kane, will host the call and provide an update on recent developments and clinical progress. Management will be answering questions live immediately following the earnings announcement part of the call.
To participate in the call, please dial +1 877-268-9044 (toll-free) in the U.S. and Canada. The conference ID number is 2680589.
| Event: | FY+ 2017 Earnings and Business Update Conference Call | |
| Date: | Thursday, March 22, 2018 | |
| Time: | 4:30pm E.T. | |
| U.S. & Canada Dial-in: | 877-268-9044 (toll free) | |
| Conference ID: | 2680589 | |
| Webcast Link: | https://edge.media-server.com/m6/p/pvvmdwpp |
A live audio webcast of the conference call will also be available on the investor relations page of Kane’s corporate website at www.kanebiotech.com In addition, the recorded conference call can be replayed and will be available for 90 days following the call on Kane’s website.
About Kane Biotech
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.
The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex®, bluestem™, AloSera™, coactiv+™ and Kane® are trademarks of Kane Biotech Inc. The Corporation is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com or contact:
Mark Ahrens-Townsend
President & CEO, Kane Biotech Inc.
[email protected]
+1 (204) 477-7592
Tirth Patel
Edison Advisors
Investor Relations
[email protected]
+1 (646) 653-7035
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
